The European Medicines Agency's (EMA's) Pharmacovigilance Risk Assessment Committee (PRAC) has started a review to evaluate the cardiovascular risks with systemic ibuprofen medicines (such as those taken by mouth but not topical medicines like creams and gels).
The cardiovascular risks being evaluated concern high-dose ibuprofen (2,400 mg per day) taken regularly for long periods. Ibuprofen is usually taken at lower doses and for short periods of time.
There is therefore no suggestion of a similar cardiovascular risk with ibuprofen as used by the overwhelming majority of patients. Ibuprofen is one of the most widely used medicines for pain and inflammation and has a well-known safety profile, particularly at usual doses.
More information is provided in the following hyperlink:
European Medicines Agency starts review of ibuprofen medicines
The Pharmacovigilance Risk Assessment Committee (PRAC) gave a recommendation on one safety review at its April meeting.
PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system
The PRAC has advised that the combined use of medicines of different classes acting on the renin-angiotensin (RAS) system, a hormone system that controls blood pressure and the volume of fluids in the body, should not be recommended. The affected medicines (called RAS-acting agents) are used particularly in the treatment of hypertension (high blood pressure) and congestive heart failure (a type of heart disease where the heart cannot pump enough blood around the body).
The PRAC recommendation will now be forwarded to the Committee for Medicinal Products for Human Use (CHMP) which will adopt the Agency’s final opinion.
More information is provided in the following hyperlink:
The information on this site is copyrighted. When use a information from this site the reference to http://bda.bg is obligatory. Reproduction of whole materials is permitted after obtaining written consent by the BDA only. The inclusion of links to materials in http://bda.bg is free.
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a review of medicines containing ambroxol or bromhexine. This follows concerns over the risk of allergic reactions with these medicines, which are widely used as expectorants (to help clear mucus from the airways).
The PRAC considers that the risk of allergic reactions is small, but has recommended that the product information for these medicines should be updated with further information on severe allergic reactions, and that severe skin reactions (SCARs) should be introduced as a side effect. SCARs include conditions such as erythema multiforme and Stevens-Johnson syndrome.
The PRAC has recommended a series of measures to address safety concerns with codeine-containing medicines when used for the management of pain in children.
The European Medicines Agency has started a review of hydroxyzine-containing medicines, which have been approved in most EU countries for a variety of uses including anxiety disorders, as premedication before surgery, for relief of pruritus (itching), and for sleep disorders.
The European Medicines Agency has started a review of testosterone-containing medicines, mainly used in men who do not produce enough testosterone (a condition known as hypogonadism).
The European Medicines Agency has started a review of the medicine Corlentor/Procoralan (ivabradine). Corlentor/Procoralan is used to treat the symptoms of adults with long-term stable angina (chest pain due to obstruction in the arteries in the heart) or long-term heart failure (when the heart cannot pump enough blood to the rest of the body).
The European Medicines Agency has started a review of medicines containing ambroxol and bromhexine, which are widely used as expectorants, as well as to relieve sore throat. Some formulations are used to treat breathing disorders in premature and newborn babies.
The European Medicines Agency has started a review of oral (by mouth) methadone medicines that also contain povidone. Methadone-containing medicines are used in rehabilitation programs in patients dependent on opioids, such as heroin, to prevent or reduce withdrawal symptoms in order to decrease the chance of relapse.
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the risks of combining different classes of medicines that act on the renin-angiotensin (RAS) system, a hormone system that controls blood pressure and the volume of fluids in the body.
The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed by majority new recommendations for zolpidem-containing medicines, used for the short-term treatment of insomnia (difficlty sleeping).
Benefits still considered to outweigh risks when given short-term and in low doses to treat nausea or vomiting.
European Medicines Agency starts review of ibuprofen medicines (23.06.2014)
PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system (24.04.2014)
PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system (24.04.2014)
European Medicines Agency concludes class review of bisphosphonates and atypical fractures
Benefit-risk review of Multaq started
European Medicines Agency recommends use of fibrates as second-line treatment